Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial-Reference-Cited by-同舟云学术

Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial

Published:2018-03 Issue:6 Volume:14 Page:515-525
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Chen Leon¹,Aria Alexander B²,Silapunt Sirunya¹,Lee Heng-Huan³,Migden Michael R⁴

Affiliation:

1. Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX 77030, USA

2. The University of Texas McGovern Medical School at Houston, Houston, TX 77030, USA

3. Department of Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA

4. Departments of Dermatology & Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract

Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be discussed in this review. Additionally, an in-depth analysis of the BOLT trial and data from the 30-month update will be included. This will serve as an update to a previously published article which reported the 12-month update of the BOLT trial.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2017-0457

Reference53 articles.

1. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations

2. Tumor Recurrence 5 Years after Treatment of Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma

3. Do basal cell carcinomas recur after complete conventional surgical excision?

4. The Genetics of Melanoma: Recent Advances

5. Increased Risk of Pancreatic Cancer in Melanoma-Prone Kindreds withp16INK4Mutations

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies;American Journal of Clinical Dermatology;2024-06-19

2. Oral smoothened inhibitors for Gorlin syndrome: A clinical review;Journal of the American Academy of Dermatology;2024-06

3. Targeted Delivery of 5-Fluorouracil and Sonidegib via Surface-Modified ZIF-8 MOFs for Effective Basal Cell Carcinoma Therapy;Pharmaceutics;2023-11-07

4. A review: FDA-approved fluorine-containing small molecules from 2015 to 2022;European Journal of Medicinal Chemistry;2023-11

5. Effects of baicalin on the proliferation of extranodal NK/T cell lymphoma cells and the sensitivity of the cells to the drug;Tropical Journal of Pharmaceutical Research;2023-04-19